Thymidine phosphorylase profiles in nonmalignant and malignant pancreatic tissue. Potential therapeutic role of capecitabine on tumoral and endothelial cells and tumor-infiltrating macrophages

L. Passantino, R. Patruno, P. Valerio, A. Penna, F. Mazzone, A. F. Zito, V. Catalano, A. Pellecchia, E. Jirillo, Girolamo Ranieri

Research output: Contribution to journalArticle


The drug capecitabine (CAP) is a thymidine Pi-deoxyribosyltransferase (TP) activated oral fluorpyrimidine that generates 5-fluorouracil (5-FU), prefentially, within tumors. Here, in 38 patients with pancreatic cancer we analyzed immunohistochemical TP expression in pancreatic cancer tissue (PCT) and adjacent nonmalignant pancreatic tissue (ANMPT). In addition, a correlation with the main clinical pathological features was made. Furthermore, TP-positive macrophages (MØ) isolated from neoplastic tissue were determined. The mean of TP-positive epithelial cells and endothelial cells in terms of microvessel density was significantly higher in PCT than in ANMPT. Because pancreatic cancer is sensitive to 5-FU, TP-activated oral CAP in tumoral and endothelial cells and tumor infiltrating MØ could increase the concentration of 5-FU at tumor site, thus resulting in an enhanced antitumor activity.

Original languageEnglish
Pages (from-to)95-107
Number of pages13
JournalImmunopharmacology and Immunotoxicology
Issue number1
Publication statusPublished - 2005



  • 5-Fluorouracile
  • Capecitabine
  • Immunohistochemistry
  • Pancreatic cancer
  • Platelet-derived endothelial cell growth factor
  • Thymidine phosphorylase

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this